Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIT: Triple Therapy for Lymphatic Filariasis, Scabies and STH in Fiji
NCT03177993Completed
- Sponsor
- Washington University School of Medicine
- Start
- Jul 2017
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of ivermectin in lymphatic filariasis (LF), scabies and soil-transmitted helminthiasis (STH) (3 arms), sponsored by Washington University School of Medicine. Primary endpoint: Frequency, type, and severity of adverse events at 7 days. Started Jul 2017; status: completed.
02
Drugs
ivermectin
03
Conditions
lymphatic filariasis (LF)scabiessoil-transmitted helminthiasis (STH)
Beyond the preview
Go deeper on NCT03177993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03177993.